Paul Sax, MD, FIDSA and clinical trialist extraordinaire David Boulware, MD, MPH, FIDSA discuss promising studies of interferon lambda, metformin, and ensitrelvir for COVID-19 -- and why none of them is currently in treatment guidelines.

*This episode was recorded before the Paxlovid EPIC-SR results were released in an FDA briefing.

This holiday season, you can help strengthen the infectious diseases workforce and support the people who advance patient care and public health every day. All donations to the IDSA Foundation through December 31 are matched up to $50,000. Learn more and double your impact at idsafoundation.org.